Eupraxia Pharmaceuticals Inc. (T:EPRX*CA)

Business Focus: Biotechnology & Medical Research (NEC)

Aug 12, 2022 07:00 am ET
Eupraxia Pharmaceuticals Reports Second Quarter 2022 Financial Results
VICTORIA, BC, Aug. 12, 2022 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced its unaudited financial results (prepared in accordance with International Financial Reporting Standards or "IFRS") and operational highlights for the second quarter ended June 30, 2022. All amounts are expressed in Canadian dollars unless otherwise indicated.
Jul 07, 2022 05:00 pm ET
Eupraxia Pharmaceuticals Recognized as Emerging Life Sciences Company of the Year by Life Sciences British Columbia
VICTORIA, BC, July 7, 2022 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company with an innovative drug delivery platform technology, announced today that it has been awarded The Emerging Life Sciences Company of the Year Award by Life Sciences British Columbia ("LSBC").
Jun 08, 2022 07:00 am ET
Eupraxia Pharmaceuticals to Present at BIO International Convention
VICTORIA, BC, June 8, 2022 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) a clinical-stage biotechnology company with an innovative drug delivery platform technology, announced today that its CEO, Dr. James Helliwell, will present at the 2022 Bio International Convention being held at the San Diego Convention Center from June 13-16, 2022, in San Diego, CA.
May 05, 2022 05:00 pm ET
Eupraxia Pharmaceuticals Reports First Quarter 2022 Financial Results
VICTORIA, BC, May 5, 2022 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced its unaudited financial results (prepared in accordance with International Financial Reporting Standards or "IFRS") and operational highlights for the first quarter ended March 31, 2022. All amounts are expressed in Canadian dollars unless otherwise indicated.
Apr 20, 2022 09:39 am ET
IIROC Trade Resumption - EPRX.WT.A
TORONTO, April 20, 2022 /CNW/ - Trading resumes in:
Apr 20, 2022 09:33 am ET
Eupraxia Pharmaceuticals Completes C$14.7 million Overnight Marketed Offering
/NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES/
Apr 20, 2022 08:23 am ET
IIROC Trading Halt - EPRX.WT.A
TORONTO, April 20, 2022 /CNW/ - The following issues have been halted by IIROC:
Apr 12, 2022 10:02 am ET
IIROC Trade Resumption - EPRX
TORONTO, April 12, 2022 /CNW/ - Trading resumes in:
Apr 12, 2022 09:48 am ET
Eupraxia Pharmaceuticals Announces Pricing of Overnight Marketed Offering
Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX:EPRX), is pleased to announce today that it has priced its previously announced overnight marketed public offering (the "Offering"). Pursuant to the Offering, Eupraxia will issue...
Apr 11, 2022 04:03 pm ET
Eupraxia Pharmaceuticals Announces Overnight Marketed Offering
Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX:EPRX), is pleased to announce it has commenced an overnight marketed public offering (the “Offering”) of units (the “Units”) of the Company. The Offering will be conducted on a best...
Apr 11, 2022 03:58 pm ET
IIROC Trading Halt - EPRX
TORONTO, April 11, 2022 /CNW/ - The following issues have been halted by IIROC:
Mar 29, 2022 07:28 pm ET
Eupraxia Pharmaceuticals Inc. Reports Fourth Quarter and Full Year 2021 Financial Results
VICTORIA, BC, March 29, 2022 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced its audited financial results (prepared in accordance with International Financial Reporting Standards or "IFRS") and operational highlights for the fourth quarter and year ended December 31, 2021. All amounts are expressed in Canadian dollars unless otherwise noted.
Jan 06, 2022 06:00 am ET
Eupraxia Pharmaceuticals to Present at H.C. Wainwright BIOCONNECT Virtual Conference
VICTORIA, BC, Jan. 6, 2022 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company with an innovative drug delivery platform technology, announced today that it will present at the H.C. Wainwright BIOCONNECT Virtual Conference taking place January 10-13, 2022.
Dec 13, 2021 04:30 pm ET
Eupraxia Pharmaceuticals Announces Filing of Preliminary Base Shelf Prospectus
VICTORIA, BC, Dec. 13, 2021 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company with an innovative drug delivery platform technology, announced today that it has filed and obtained a receipt for a preliminary short form base shelf prospectus with the securities regulatory authorities in each of the provinces and territories of Canada.
Dec 02, 2021 04:00 pm ET
Eupraxia Pharmaceuticals Inc. Provides Update on its Phase 2 Trial for Osteoarthritis Drug Candidate EP-104IAR
Management mitigating risk by adding clinical sites in two countries and making protocol changes Timing for top-line results remains unchanged, still expected in Q4 2022 VICTORIA, BC, Dec. 2, 2021 /CNW/ - December 2, 2021 - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company with an innovative drug delivery platform technology, today provided an update on its ongoing Phase 2 trial that is evaluating the safety and efficacy of its drug candidate EP-104IAR as a treatment for knee osteoarthritis.
Nov 10, 2021 05:54 pm ET
Eupraxia Pharmaceuticals Inc. Reports Third Quarter 2021 Financial Results
VICTORIA, BC, Nov. 10, 2021 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced its unaudited financial results (prepared in accordance with International Financial Reporting Standards or "IFRS") and operational highlights for the third quarter ended September 30, 2021. All amounts are expressed in Canadian dollars unless otherwise noted.
Nov 04, 2021 07:00 am ET
Eupraxia Pharmaceuticals Inc. Announces Research and Development Funding
VICTORIA, BC, Nov. 4, 2021 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery platform technology, today announced it is receiving advisory services and funding up to $700,000 from the National Research Council of Canada Industrial Research Assistance Program ("NRC IRAP") to support a research and development project to further develop the Company's polymer-based proprietary drug delivery technology.
Sep 16, 2021 05:00 pm ET
Eupraxia Pharmaceuticals Inc. Provides Update for Phase 2 Osteoarthritis Drug Candidate EP-104IAR
EP-104IAR Phase 1 study results published in Osteoarthritis and Cartilage Open Company continues to expand its patent estate for EP-104IAR with patent grant in Israel VICTORIA, BC, Sept. 16, 2021 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company with an innovative drug delivery platform technology, today announced an update for its lead osteoarthritis (OA) drug candidate EP-104IAR.
Sep 14, 2021 05:00 pm ET
Eupraxia Pharmaceuticals Inc. Commences Patient Screening For Its Phase 2 Trial For Osteoarthritis Drug Candidate EP-104IAR
Company also reaffirms data readout timelines for its Phase 2 trial VICTORIA, BC, Sept. 14, 2021 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company with an innovative drug delivery platform technology, today announced that it has started screening patients for inclusion into its Phase 2 trial, which is evaluating EP-104IAR's efficacy and safety as a treatment for knee osteoarthritis.
Sep 08, 2021 05:00 pm ET
Eupraxia Pharmaceuticals Inc. Announces Presentation at H.C. Wainwright 23rd Annual Global Investment Conference
VICTORIA, BC, Sept. 8, 2021 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery platform technology, today announced that senior management will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference, held virtually September 13-15, 2021.
Aug 13, 2021 05:00 pm ET
Eupraxia Pharmaceuticals Inc. Provides Corporate Update and Reports Second Quarter 2021 Financial Results
VICTORIA, BC, Aug. 13, 2021 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced its unaudited financial results (prepared in accordance with International Financial Reporting Standards or "IFRS") and operational highlights for the second quarter ended June 30, 2021. All amounts are expressed in Canadian dollars unless otherwise noted.
Jul 19, 2021 07:00 am ET
Eupraxia Pharmaceuticals Inc. Announces Authorization of Clinical Trial Application for Phase 2 Trial of EP-104IAR in Osteoarthritis of the Knee
VICTORIA, BC, July 19, 2021 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced the authorization of its Clinical Trial Application ("CTA") by the Danish Medicines Agency ("DKMA"). The authorization is required to initiate the Company's Phase 2 clinical trial for its lead candidate EP-104IAR as a potential treatment for pain from osteoarthritis ("OA") of the knee.
Jun 21, 2021 05:00 pm ET
Eupraxia Pharmaceuticals Inc. Announces $10 Million Convertible Debt Agreement with Silicon Valley Bank and Conversion of $6.0 Million pre-IPO Debt
VICTORIA, BC, June 21, 2021 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced that it has entered into a contingent convertible debt agreement (the "Agreement") with Silicon Valley Bank ("SVB") and concurrently drew down in full the $10 million principal amount under the Agreement. In addition, the Company announces the conversion of approximately $6.0 million of outstanding indebtedness into common shares of the Company ("Common Shares") pursuan
Jun 16, 2021 12:08 pm ET
Eupraxia Pharmaceuticals Inc. Announces Presentation at the Raymond James Human Health Innovations Conference
VICTORIA, BC, June 16, 2021 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced that senior management will deliver a corporate presentation on June 23, 2021, at 2:00 p.m. ET at the Virtual Raymond James Human Health Innovations Conference.   
May 13, 2021 09:15 pm ET
Eupraxia Pharmaceuticals Inc. Provides Corporate Update and Reports First Quarter 2021 Financial Results
VICTORIA, BC, May 13, 2021 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced its financial results and operational highlights for the first quarter ended March 31, 2021. All amounts are expressed in Canadian dollars unless otherwise noted.
May 03, 2021 07:00 am ET
Eupraxia Pharmaceuticals Inc. Announces Appointment of Bruce Cousins as President & CFO
VICTORIA, BC, May 3, 2021 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced that it has appointed industry veteran Bruce Cousins as the Company's new President and Chief Financial Officer.
Apr 14, 2021 05:00 pm ET
Eupraxia Pharmaceuticals Enters Collaborative Partnership with NBCD for Lead Osteoarthritis (OA) Product Candidate
NBCD (Nordic Bioscience Clinical Development) to make strategic investment on the same terms of Eupraxia's recently completed IPO VICTORIA, BC, April 14, 2021 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced that it has entered into an agreement (the "CTO Agreement") with NBCD A/S ("NBCD"), a contract research organisation dedicated to clinical drug development and research in OA, to conduct Eupraxia's EP-104IAR Phase 2 clinical trial that will initia
Apr 13, 2021 05:00 pm ET
Eupraxia Pharmaceuticals Inc. to Present at Bloom Burton & Co. Healthcare Investor Conference
VICTORIA, BC, April 13, 2021 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced that Dr. James Helliwell, President and Chief Executive Officer of Eupraxia will present at the Bloom Burton & Co. Healthcare Investor Conference on Tuesday April 20, 2021 at 4:00 pm ET.
Apr 09, 2021 09:00 am ET
TMX Group Equity Financing Statistics - March 2021
Toronto Stock Exchange, TSX Venture Exchange
Mar 19, 2021 11:30 am ET
Eupraxia Virtually Opens The Market
TORONTO, March 19, 2021 /CNW/ - James Helliwell, President and Chief Executive Officer, Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), and his team joined Dani Lipkin, Director, Global Business Development, TMX Group to celebrate the Company's new listing on Toronto Stock Exchange and open the market.
Mar 09, 2021 08:33 am ET
IIROC Trade Resumption - EPRX
TORONTO, March 9, 2021 /CNW/ - Trading resumes in:
Mar 09, 2021 08:27 am ET
Eupraxia Pharmaceuticals Inc. Completes Initial Public Offering
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES/
Mar 09, 2021 06:57 am ET
IIROC Trading Halt - EPRX
TORONTO, March 9, 2021 /CNW/ - The following issues have been halted by IIROC:
Mar 03, 2021 03:14 pm ET
Eupraxia Pharmaceuticals Inc. Files Final Prospectus and Announces Pricing of Initial Public Offering
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES/

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.